Stallergenes Greer names Tibor Nemes head of technical ops

2 February 2016

Stallergenes Greer (Euronext Paris: STAGR) has appointed Tibor Nemes as global head of technical operations.

Fereydoun Firouz, chairman and chief executive of Stallergenes Greer, said: “In this new role, Tibor will lead our Technical Operations organization, craft our global manufacturing strategy, and ensure our teams execute to the highest standards of operational excellence. He will play a vital role in helping our Company become the leading biopharmaceutical company focused on enabling people with allergies to live normal lives.”

Mr Tibor has 20 years of experience in the biotech and pharmaceutical industry in both Europe and in the USA. Most recently he was heading operations for manufacturing strategy and business development & licensing within global technical at Swiss pharma giant Novartis (VX: NOVN).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK